Department of Biotechnology, Yonsei University, Seoul, Republic of Korea.
Adv Drug Deliv Rev. 2012 Jan;64(1):40-52. doi: 10.1016/j.addr.2011.09.005. Epub 2011 Sep 24.
Genetic medicines that induce angiogenesis represent a promising strategy for the treatment of ischemic diseases. Many types of nonviral delivery systems have been tested as therapeutic angiogenesis agents. However, their delivery efficiency, and consequently therapeutic efficacy, remains to be further improved, as few of these technologies are being used in clinical applications. This article reviews the diverse nonviral gene delivery approaches that have been applied to the field of therapeutic angiogenesis, including plasmids, cationic polymers/lipids, scaffolds, and stem cells. This article also reviews clinical trials employing nonviral gene therapy and discusses the limitations of current technologies. Finally, this article proposes a future strategy to efficiently develop delivery vehicles that might be feasible for clinically relevant nonviral gene therapy, such as high-throughput screening of combinatorial libraries of biomaterials.
基因药物诱导血管生成是治疗缺血性疾病的一种很有前途的策略。许多类型的非病毒传递系统已被测试作为治疗性血管生成剂。然而，它们的传递效率，因此治疗效果，仍然有待进一步提高，因为这些技术很少被应用于临床应用。本文综述了应用于治疗性血管生成领域的多种非病毒基因传递方法，包括质粒、阳离子聚合物/脂质、支架和干细胞。本文还回顾了采用非病毒基因治疗的临床试验，并讨论了当前技术的局限性。最后，本文提出了一种未来的策略，以有效地开发可能适用于临床相关的非病毒基因治疗的传递载体，例如生物材料组合文库的高通量筛选。
